Condition (MeSH)
Urinary Calculi
ClinicalTrials.gov lists 611 trials for Urinary Calculi or a narrower condition beneath it. Allena Pharmaceuticals has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
93 of the 611 trials are tagged with Urinary Calculi itself; the rest are tagged with a narrower condition beneath it.
When did Urinary Calculi trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 71
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 74 |
| 2025 | 71 |
| 2024 | 39 |
| 2023 | 37 |
| 2022 | 48 |
| 2021 | 48 |
| 2020 | 33 |
| 2019 | 36 |
| 2018 | 24 |
| 2017 | 19 |
Showing 10 of 28 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 89 trials starting in 2026 and about 74 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 31 months from start to primary completion across 81 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 301 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Urinary Calculi trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 15 |
| Phase 1/2 | 9 |
| Phase 2 | 30 |
| Phase 2/3 | 3 |
| Phase 3 | 23 |
| Phase 4 | 43 |
| Not applicable | 361 |
| Observational | 127 |
How many Urinary Calculi trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 48 |
| Recruiting | 95 |
| Enrolling by invitation | 10 |
| Active, not recruiting | 26 |
| Completed | 256 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Urinary Calculi trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Allena Pharmaceuticals | 7 |
Which drugs are being tested for Urinary Calculi? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Tamsulosin | 18 |
| ALLN-177 | 5 |
| ALFUZOSIN | 4 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| sildosin 4mg | 7 |
| PO Morphine | 5 |
| Furosemide-IR | 3 |
| General Anesthesia | 3 |
| Standard Care | 3 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Urinary Calculi trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Severe urinary tract infection | 7 | 1 |
| Infection: Urinary Tract | 6 | 1 |
| Acute Cholecystitis | 5 | 1 |
| Pregnancy | 5 | 1 |
| Renal colic | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Urinary Calculi? (146)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Using structured problem solving to promote fluid consumption in the prevention of urinary stones with hydration (PUSH) trial. | BMC nephrology | 2024 | Yes |
| Adjudication of Self-reported Symptomatic Stone Recurrence in the Prevention of Urinary Stones With Hydration Trial. | Urology | 2024 | Yes |
| In Pursuit of the Optimal Dusting Settings with the Thulium Fiber Laser: An <i>In Vitro</i> Assessment. | Journal of endourology | 2023 | Yes |
| The Use of a Virtual Reality Device (HypnoVR) During Extracorporeal Shockwave Lithotripsy for Treatment of Urinary Stones: Initial Results of a Clinical Protocol. | Urology | 2023 | Yes |
| Pulsed thulium:YAG laser-ready to dust all urinary stone composition types? Results from a PEARLS analysis. | World journal of urology | 2023 | Yes |
Showing 5 of 146 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.